Ocera Therapeutics Completes First in Human Studies with OCR-002 for the Treatment…
SAN DIEGO, Dec. 15, 2010 /PRNewswire/ — Ocera Therapeutics, Inc. announced today that it has completed two studies evaluating the safety and pharmacokinetics of OCR-002 (ornithine phenylacetate) which includes healthy volunteers and pat…